Previous close | 15.40 |
Open | 15.42 |
Bid | 14.54 x N/A |
Ask | 15.26 x N/A |
Day's range | 14.84 - 15.42 |
52-week range | 5.42 - 16.78 |
Volume | |
Avg. volume | 16 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARSIPPANY, N.J. & TEL AVIV & PARIS, May 08, 2024--ACCESS HERE THE COMPLETE PRESS RELEASE
MONTPELLIER, France, May 08, 2024--Regulatory News: The listing of the Medincell (Paris:MEDCL) shares on Euronext Paris has been suspended at the request of the Company, pending the publication of a press release. Trading on Euronext Paris will resume tomorrow at the opening of markets.
MONTPELLIER, France, April 16, 2024--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. A